CML Diagnosis and Monitoring
In CML, one blood test tells you how well treatment is working. Understanding what it measures makes the follow-up schedule far easier to live with.
In summary
Short answer: CML is confirmed by testing for the BCR-ABL fusion gene in blood or bone marrow. The level measured at diagnosis becomes the baseline, and repeat testing during treatment shows directly whether the therapy is working.
How the diagnosis is confirmed
Short answer: Suspicion usually begins with a blood count showing a raised white cell count. Confirmation comes from detecting BCR-ABL, using cytogenetic testing, FISH or PCR. A bone marrow examination is generally performed as well, because it establishes the phase of the disease. Nearly all patients are diagnosed in chronic phase, which is where treatment works best, and identifying phase correctly at the start matters for everything that follows.
What BCR-ABL monitoring actually measures
PCR testing measures how much BCR-ABL is present relative to a reference gene, giving a percentage. That number is compared with the baseline taken at diagnosis and tracked over time. A steadily falling value indicates the treatment is working. Because the test detects disease at levels far below what a blood count or a symptom would reveal, it gives an early and sensitive picture of response.
Why monitoring continues even when you feel well
Feeling well is not evidence that the disease is controlled. Many patients with CML feel entirely normal while their BCR-ABL level is rising, which is precisely why scheduled testing exists. Monitoring is not a formality; it is the mechanism by which a problem is caught while it is still straightforward to address.
What happens if the level stops falling or rises
A plateau or a rise prompts a structured review rather than an immediate change of drug. The first questions are usually practical: has adherence slipped, and is another medicine or supplement interfering with absorption? Resistance testing may be considered. Depending on the findings, the response may be a change of agent, a dose adjustment, or closer monitoring. This is a common and manageable situation, not a failure.
Where this fits in treatment
For the full clinical overview, see CML treatment in Gurugram. If you are weighing a treatment decision, a second opinion reviews the diagnosis and the plan together.
Related questions
Testing is more frequent in the first year of treatment and generally spaces out once a stable response is achieved. The exact schedule is set by the treating specialist based on how the disease responds.
Not necessarily. Adherence, drug interactions and laboratory variation are all checked first. A rise is a signal to investigate, and there are usually several options available.
Speak to Dr. Ramawat
Dr. Ramawat currently consults at the American Oncology Institute, Gurugram. Call directly or send your details on WhatsApp.